Name: | exenatide |
---|---|
PubChem Substance ID: | 3814631 |
Synonyms: |
Extendin-4; 141732-76-5; Exendin 4
|
Name: | exenatide |
---|---|
Name (isomeric): | DB01276 |
Drug Type: | biotech |
Synonyms: |
AC2993; Synthetic exendin-4
|
Brand: | Byetta, Byetta (Amylin/Eli Lilly) |
CAS number: | 141758-74-9 |
Indication: | Indicated as adjunctive therapy to improve glycemic control in patients with Type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of both, but have not achieved adequate glycemic control. |
---|---|
Pharmacology: |
Exenatide is an incretin mimetic, which has glucoregulatory effects. While it is has blood-sugar lowering actions alone, it can also be combined with other medications such as pioglitazone, metformin, sulfonylureas, and/or insulin to improve glucose control. The approved use of exenatide is with either sulfonylureas, metformin and thiazolinediones....
show more » |
Mechanism of Action: |
Exenatide is a functional analog of the human incretin Glucagon-Like Peptide-1 (GLP-1). Incretins enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. The GLP-1 system increases insulin secretion only in the presence of elevated plasma glucose levels, avoi...
show more » |
Absorption: | Following subcutaneous administration to patients with type 2 diabetes, exenatide reaches median peak plasma concentrations in 2.1 hours. |
Route of elimination: | Nonclinical studies have shown that exenatide is predominantly eliminated by glomerular filtration with subsequent proteolytic degradation. |
Half Life: | Mean terminal half-life is 2.4 hours. |
Clearance: | Apparent cl=9.1 L/hr |
Toxicity: | Effects of the overdoses included severe nausea, severe vomiting, and rapidly declining blood glucose concentrations. |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|